Cephalon Inc. (NASDAQ: CEPH) recently announced its strategic alliance with
Mesoblast Limited to develop and commercialize novel adult Mesenchymal Precursor
Stem Cell (MPC) therapeutics for degenerative conditions of the cardiovascular
and central nervous systems. The degenerative conditions include Congestive
Heart Failure, Acute Myocardial Infarction, Parkinsons disease, and Alzheimers
disease. The alliance also extends to products for augmenting hematopoietic stem
cell transplantation in cancer patients. As per the terms of the agreement
between the companies, in exchange for exclusive world-wide rights to
commercialize specific products based on Mesoblasts proprietary adult stem cell
technology platform. The company will make an upfront payment to Mesoblast
totaling US$130 million (US$30 million upon Mesoblast shareholder approval) and
regulatory milestone payments of up to US$1.7 billion. Mesoblast will be
responsible for the conduct and expenses of certain Phase IIa clinical trials
and commercial supply of the products. The company will be responsible for all
Phase IIb and III clinical trials and subsequent commercialization of the
products. Mesoblast will hold all manufacturing rights and will share
significantly in the net product sales. Cephalon engages in the discovery,
development and commercialization of products in four core therapeutic areas
including central nervous system (CNS), pain, oncology and inflammatory disease.
Celgene Corporation (NASDAQ: CELG) recently announced the evaluation of its next
IMiD compound, pomalidomide in three separate investigational trials of patients
with multiple myeloma who were relapsed or refractory after prior treatments
including lenalidomide, thalidomide and bortezomib. Celgene Corporation iengages
in the discovery, development and commercialization of therapies designed to
treat cancer and immune-inflammatory related diseases. Amgen Inc. (NASDAQ: AMGN)
recently announced positive top-line results from a Phase 3 trial evaluating
XGEVA (denosumab) versus placebo in 1,432 men with castrate-resistant prostate
cancer. The trial, identified as the 147 study, showed that XGEVA significantly
improved median bone metastasis-free survival by 4.2 months (HR=0.85, 95 percent
CI 0.73-0.98, p=0.03) compared to placebo (primary endpoint), and significantly
improved time to first occurrence of bone metastases (secondary endpoint). The
overall survival was similar between the XGEVA and placebo groups (secondary
endpoint). Amgen is in the business of discovery, development, manufacturing and
marketing medicines for grievous illnesses. Biogen Idec Inc. (NASDAQ: BIIB)
announced that it provided grants to twelve prestigious universities and medical
centers across the country for the 2010-2011 academic year. The grants were
awarded through the Biogen Idec MS Clinical Fellowship Program and provided a
total of $900,000 to recipients for the placement of clinical MS Fellows. Biogen
Idecs products include AVONEX, RITUXAN, TYSABRI and FUMADERM. Gilead Sciences
Inc. (NASDAQ: GILD) recently announced that it has submitted a New Drug
Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing
approval of the single-tablet regimen of Truvada (emtricitabine and tenofovir
disoproxil fumarate) and Tibotec Pharmaceuticals' investigational
non-nucleoside reverse transcriptase inhibitor TMC278 (rilpivirine
hydrochloride) for HIV-1 infection in adults. This would be the second product
that contains a complete HIV treatment regimen in a single once-daily tablet, if
approved. Gilead discovers, develops and commercializes therapeutics and is a
biopharmaceutical company. This corporate profile is provided for information
purposes only and should not be used as the basis for any investment decision.
We are neither licensed nor qualified to provide investment advice. We were not
paid, nor do we hold a position in these stocks. We reserve the right to buy or
sell CEPH, CELG, AMGN, BIIB and GILD at any time after this post.
No comments:
Post a Comment